Development of autotaxin inhibitors: An overview of the patent and primary literature: Miniperspective
D Castagna, DC Budd, SJF Macdonald… - Journal of medicinal …, 2016 - ACS Publications
D Castagna, DC Budd, SJF Macdonald, C Jamieson, AJB Watson
Journal of medicinal chemistry, 2016•ACS PublicationsThe autotaxin–lysophophatidic acid (ATX–LPA) signaling pathway is implicated in a variety
of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic
diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a
result, ATX–LPA has become of significant interest within both the industrial and the
academic communities. This review aims to provide a concise overview of the development
of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic
diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a
result, ATX–LPA has become of significant interest within both the industrial and the
academic communities. This review aims to provide a concise overview of the development
of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
The autotaxin–lysophophatidic acid (ATX–LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among others. As a result, ATX–LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.
ACS Publications